Evidence map›Paper›PMID 38190580›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.

Stefania Morganti, Christopher J Gibson, Qingchun Jin, Katheryn Santos, Ashka Patel, Alex Wilson, Margaret Merrill, Julie Vincuilla, Samantha Stokes, Marla Lipsyc-Sharf and 13 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07675967 (Clonal Hematopoiesis Chemotherapy and Radiation Effects Study), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07675967 recruitingnot on this mapstarted 2025, after this paper: background citation

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

TypeobservationalSponsorDana-Farber Cancer InstituteRan2025 to 2035Enrolled5,000ConditionsLung Cancer (Diagnosis), Osteochondroma, Spitz Nevus, Solid CancersArmsSamples
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Risk factors of clonal hematopoiesis of indeterminate potential.Clinical medicine (London, England) · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Comment on "Clonal hematopoiesis of indeterminate potential and breast cancer risk".International journal of surgery (London, England) · 2026
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Clonal Hematopoiesis in Women With Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 2 countries.

Stefania MorgantiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-5284-9944
Christopher J GibsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-3700-5310
Qingchun JinDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-6388-5123
Katheryn SantosDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-3945-7644
Ashka PatelDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Alex WilsonBroad Institute of MIT and Harvard, Cambridge, MA.ORCID 0009-0006-4689-7812
Margaret MerrillDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Julie VincuillaDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA.
Samantha StokesBroad Institute of MIT and Harvard, Cambridge, MA.
Marla Lipsyc-SharfDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-4071-6383
Tonia ParkerDivision of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA.
Tari A KingBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.
Elizabeth A MittendorfBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.ORCID 0000-0002-9762-8536
Giuseppe CuriglianoDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.ORCID 0000-0003-1781-2518
Melissa E HughesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Daniel G StoverOhio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0001-9003-8165
Sara M TolaneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-5940-8671
Lachelle D WeeksDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-8726-6212
Nabihah TayobDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-6088-167X
Nancy U LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-2263-5413
Judy E GarberDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-9449-3982
Peter G MillerHarvard Medical School, Boston, MA.ORCID 0000-0002-6797-9335
Heather A ParsonsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-8178-6612
Broad Institute · USHarvard University · USBrigham and Women's Hospital · USDana-Farber Cancer Institute · USMassachusetts General Hospital · USThe Ohio State University · USUniversity of Milan · IT

Funding

Tissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI LEIF W ELLISEN, NANCY U LIN · 2013 to 2026
$30.1M
Can a subset of patients with HER2+ metastatic breast cancer be cured?K08CA252639 · NCI · FRED HUTCHINSON CANCER CENTER · PI PARSONS, HEATHER ANNE · 2021 to 2025
$1.3M
Role of PPM1D and PPM1D mutations in hematopoiesis and response to stressK08CA263183 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, PETER GRANT · 2021 to 2025
$1.1M
NCI NIH HHS K08 CA252639NCI NIH HHS K08 CA263183NCI NIH HHS P50 CA168504
6 · The paper itself

Abstract

purposeClonal hematopoiesis of indeterminate potential (CHIP) is frequent in patients with solid tumors. Prospective data about CHIP prevalence at breast cancer diagnosis and its dynamic evolution under treatment selective pressure are limited. PATIENTS AND

methodsWe performed targeted error-corrected sequencing on 614 samples from 380 patients with breast cancer. We investigated the dynamics of CHIP on prospectively collected paired samples from patients with early breast cancer (eBC) receiving chemotherapy (CT) or endocrine therapy (ET). We assessed the correlation of CHIP with survival in patients with metastatic triple-negative breast cancer (mTNBC). We estimated the risk of progression to treatment-related myeloid neoplasms (t-MN) according to the clonal hematopoiesis risk score (CHRS). In exploratory analyses, we considered clonal hematopoiesis (CH) with variant allele fraction (VAF) ≥0.005.

resultsCHIP was identified in 15% of patients before treatment. Few CHIP emerged after treatment, and the risk of developing new mutations was similar for patients receiving CT versus ET (odds ratio [OR], 1.16;

conclusionCHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However,

Indexed as

Breast NeoplasmsClonal HematopoiesisAdultAgedAged, 80 and overFemaleHumansMiddle AgedMutationPrevalencePrognosisProspective StudiesTriple Negative Breast Neoplasms

Identifiers

PMID38190580
PMCPMC11795512
OpenAlexW4390660487

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.